![]() Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Management of bone metastases in prostate cancer: a review. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases. Pathogenesis of osteoblastic bone metastases from prostate cancer. Ibrahim T, Flamini E, Mercatali L, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. Metastatic prostate cancer and the bone: significance and therapeutic options. Gartrell BA, Coleman R, Efstathiou E, et al. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. In this paper we extensively review the literature on the use of radium-223 dichloride in metastatic castration-resistant prostate cancer.įerlay J, Soerjomataram I, Dikshit R, et al. The therapeutic landscape of metastatic skeletal cancer significantly changed after the introduction of radium-223, the first bone-homing radiopharmaceutical with disease-modifying properties. Many studies in recent decades have demonstrated the efficacy of various radiopharmaceuticals, including strontium-89 and samarium-153, for palliation of pain from diffuse skeletal metastases, but no significant benefit in terms of disease progression and overall survival has been shown. The current therapeutic armamentarium includes conventional analgesics, chemotherapeutic agents, immunotherapy, androgen-deprivation therapy, osteoclast inhibitors (bisphosphonates, denosumab), surgical interventions, external-beam radiotherapy and radionuclide metabolic therapy. The onset of skeletal metastases is typical of advanced-stage prostate cancer and requires a multidisciplinary approach to alleviate bone pain and try to delay disease progression.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |